Kusajili – Centralise les essais cliniques mondiaux

Résultat de votre recherche par promoteur : Beaufour Ipsen Pharma-Ipsen Biotech Department

Femme et Homme Max 99 ans
Beaufour Ipsen Pharma-Ipsen Biotech Department MAJ Il y a 4 ans

Phase III multicentre, Randomised, Double Blind, Comparative study to assess the efficacy and safety of lanreotide 30mg versus placebo as a palliative treatment of clinical symptoms associated with intestinal obstruction due to peritoneal carcinomatosis in inoperable patients The primary objective of this study is to assess the efficacy of lanreotide 30 mg as compared to placebo to relieve clinical symptoms due to small bowel obstruction in inoperable patients with periton...

Pays Aucun
Organes Aucun
Spécialités Aucune

Essai clos aux inclusions

Plus d'informations